10-Q: United-Guardian Q1 2026 Sales Surge on Pharma and Cosmetics

United-Guardian reports a 16% increase in Q1 2026 net sales, driven by strong performance in pharmaceutical products and cosmetic ingredients, alongside a significant settlement income.

Summary

• United-Guardian's net sales for the first quarter of 2026 increased by 16% to $2,872,222 compared to $2,481,127 in the first quarter of 2025.
• This growth was primarily driven by a 24% increase in pharmaceutical product sales (Renacidin and Clorpactin WCS-90) and a 21% increase in cosmetic ingredient sales.
• Medical lubricant sales saw a slight decrease of 5%.
• Cost of sales as a percentage of net sales increased from 45% to 50%, attributed to a higher proportion of pharmaceutical product sales.
• Operating expenses increased by 5%, mainly due to higher selling, general, and administrative expenses.
• Research and development expenses remained relatively flat.
• Investment income decreased by 18% due to lower interest rates.
• A significant settlement income of $303,133 was recognized related to a contract manufacturer's facility shutdown in 2023-2024.
• Net income for the quarter was $818,902, an increase from $560,895 in the prior year period.
• Earnings per share (basic and diluted) rose to $0.18 from $0.12.
• Cash from operations increased significantly to $604,536 from $322,080.
• The company declared a dividend of $0.25 per share in Q1 2026, down from $0.35 per share in Q1 2025.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive filing, with strong top-line growth, improved profitability, and strategic initiatives in high-growth segments, despite some cost pressures and a decrease in cash reserves.

Positives

• Net sales increased by 16% to $2,872,222 in Q1 2026 compared to $2,481,127 in Q1 2025.
• Pharmaceutical product net sales increased by 24% to $1,445,324.
• Cosmetic ingredient sales increased by 21% to $843,907, driven by ASI resuming regular purchases.
• Net income increased to $818,902 from $560,895.
• Earnings per share increased to $0.18 from $0.12.
• Cash flow from operating activities more than doubled to $604,536.
• A favorable settlement of $303,133 was recognized.
• The company has secured approval from two major Pharmacy Benefit Managers for Renacidin to be included on their formularies starting in 2026.
• A new distribution agreement was signed with Brenntag Specialties for sexual wellness ingredients in the US, Canada, Mexico, and France.
• The current ratio improved to 8.1:1 from 7.3:1.

Negatives

• Cost of sales as a percentage of net sales increased to 50% from 45%, due to a higher proportion of higher-cost pharmaceutical products.
• Medical lubricant sales decreased by 5%.
• Investment income decreased by 18% due to lower interest rates.
• The company declared a lower dividend per share ($0.25) compared to the prior year ($0.35).
• Cash and cash equivalents decreased significantly from $1,251,097 to $735,854.
• Accounts payable decreased significantly by $366,247, which contributed to the decrease in cash.

Risks

• Global supply chain instability and inflation can increase freight costs and raw material prices.
• Changes in U.S. trade policies, tariffs, and retaliatory measures by other countries could negatively impact sales volume, prices, and costs.
• Concentration of credit risk exists with three pharmaceutical distributors and one cosmetic ingredient distributor accounting for 75% of gross sales and accounts receivable.
• Supplier concentration risk exists with three major raw material vendors accounting for 83% of purchases.
• Reliance on a single contract manufacturer for Renacidin poses a risk of disruption.
• Global competition from lower-priced Asian and European companies in the cosmetic ingredients market.
• Potential for increased Medicare Part D rebates impacting future profitability.
• The company's financial condition and results of operations could be adversely affected by geopolitical tensions and conflicts in key energy-producing regions.

Future Outlook

The company is well-positioned for future growth by leveraging its expertise in specialty ingredients and capitalizing on emerging market opportunities. A new distribution agreement for sexual wellness ingredients in the US, Canada, Mexico, and France is expected to contribute to growth. The company will continue its insurance payer outreach program for Renacidin and introduce a new program to increase healthcare professional awareness. Management expects to continue using cash for dividend payments, purchasing marketable securities, and pursuing growth opportunities.

Management Comments

• "With a refined product portfolio and strategic partnerships, we are well-positioned for future growth, leveraging our expertise in specialty ingredients to capitalize on emerging market opportunities."
• "The sexual wellness segment is expected to grow at a higher compound annual growth rate (CAGR) than other segments such as skin care, personal care and cosmetics."
• "Our management team and Board of Directors continue to closely monitor our investment portfolio and have made and will continue to make any changes they believe may be necessary or appropriate to minimize the future impact on our financial position that the volatility of the global financial markets may have."
• "The Company believes that its working capital is, and will continue to be, sufficient to support its operating requirements for at least the next twelve months."

Industry Context

StockSavvy.ai notes that United-Guardian's Q1 2026 results reflect a growing demand for specialized ingredients in the cosmetic and personal care sectors, particularly those with a focus on natural and environmentally friendly materials. The company's strategic move into the sexual wellness segment aligns with broader industry trends indicating higher growth potential compared to traditional skincare and cosmetics. The pharmaceutical segment's performance, especially for Renacidin, highlights the ongoing importance of specialized healthcare products and the impact of formulary approvals.

Comparison to Industry Standards

• The 16% year-over-year net sales growth for United-Guardian in Q1 2026 is robust, particularly within the specialty chemical and pharmaceutical sectors, which often experience more moderate growth rates.
• The increase in the cost of sales as a percentage of net sales (from 45% to 50%) is a point of attention. While attributed to a higher mix of pharmaceutical products, this trend needs to be monitored against industry benchmarks for gross margins in the pharmaceutical ingredient and specialty chemical sectors.
• The company's focus on R&D for naturally-derived products aligns with a significant trend across the cosmetic and personal care industries, where major players like L'Oréal, Estée Lauder, and Unilever are increasingly investing in sustainable and natural ingredient innovation.
• The penetration of sexual wellness ingredients is a niche but rapidly growing area. Companies like Reckitt Benckiser (with its Durex brand) and private label manufacturers are key players, and United-Guardian's entry via distribution agreements with Brenntag Specialties positions it to capture growth in this segment, which is projected to outpace broader personal care markets.
• The pharmaceutical product Renacidin's performance and efforts to secure formulary approvals are critical. In the pharmaceutical sector, market access and reimbursement are key drivers of success, similar to how companies like Pfizer and Merck navigate complex healthcare systems to ensure their drugs reach patients and are covered by insurance.

Legal Proceedings

• None mentioned in the filing.

Related Party Transactions

• The Company paid PKF OConnor Davies (PKF) $9,833 in Q1 2026 and $4,000 in Q1 2025 for accounting and tax services. Lawrence Maietta, a former partner at PKF, is a director of the Company and a senior consultant at PKF.

Stakeholder Impact

• Shareholders: Increased net income and EPS are positive. Reduced dividend per share may be a concern for income-focused investors. The company's strategic focus on growth segments like sexual wellness could lead to long-term value appreciation.
• Employees: The company accrued $20,000 in 401(k) contributions for Q1 2026, down from $28,750 in Q1 2025, and no discretionary contributions were made for 2025 due to reduced sales and earnings. This could indicate a more cautious approach to employee benefits or compensation.
• Suppliers: The company relies on three major raw material vendors for 83% of its purchases, indicating a potential risk for suppliers if these relationships are disrupted.
• Creditors: The company's strong current ratio (8.1:1) and sufficient working capital suggest a low risk for creditors in the short term.

Next Steps

• Continue insurance payer outreach program for Renacidin.
• Introduce a new outreach program to increase awareness among healthcare professionals for Renacidin.
• Begin manufacturing and distribution of the new Natrajel line of sexual wellness ingredients once orders are received.
• Receive remaining product covered by the contract manufacturer settlement, valued at approximately $35,000, during the second quarter of 2026.
• Continue to monitor investment portfolio and make necessary adjustments.
• Continue to support operating requirements with working capital for at least the next twelve months.
• Expect to continue using cash for dividend payments, purchasing marketable securities, and pursuing growth opportunities.

Key Dates

Recommendation

The company demonstrates strong operational performance with significant sales and profit growth, driven by key product lines and a favorable settlement. Strategic initiatives in growing markets like sexual wellness are positive. However, increased cost of sales, a decrease in cash reserves, and a reduced dividend per share warrant a cautious approach. While the outlook is positive, the reliance on a few key customers and suppliers, coupled with global economic uncertainties, suggests a 'hold' recommendation pending further clarity on margin stabilization and cash flow management.

Keywords

United-Guardian, Form 10-Q, Quarterly Report, Financial Statements, Pharmaceuticals, Cosmetic Ingredients, Sexual Wellness, Medical Lubricants, Renacidin, Clorpactin WCS-90, Net Sales, Net Income, Earnings Per Share, Cash Flow, Dividends, SEC Filing